t Hart B A, Otten H G
Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
Pharm World Sci. 1995 Nov 24;17(6):178-85. doi: 10.1007/BF01870608.
The main challenge in the development of new modalities for the treatment of rheumatoid arthritis is to enhance the specificity while reducing the adverse side-effects of therapeutics. Biotechnology provides a variety of reagents, such as monoclonal antibodies, recombinant cytokines, cytokine antagonists, and small peptides, with the potential to interfere with selected stages of the disease process in a highly specific manner. In addition, several new therapeutic approaches have emerged as a result of extensive research with animal models of disease, including T-cell vaccination and bone marrow transplantation. This article discusses current insights into the pathogenesis of rheumatic diseases, focusing on rheumatoid arthritis. A number of new therapeutic modalities for rheumatoid arthritis, in particular those acting on the immune system, are discussed. Because it is not possible to provide a complete overview of all the developments in the field in limited space, a selection of strategies and modalities which are representative of the broad variety of immunotherapeutic approaches currently used are highlighted.
类风湿关节炎新治疗方法研发中的主要挑战在于提高治疗的特异性，同时减少其副作用。生物技术提供了多种试剂，如单克隆抗体、重组细胞因子、细胞因子拮抗剂和小肽，它们有可能以高度特异性的方式干扰疾病进程的特定阶段。此外，通过对疾病动物模型的广泛研究，还出现了几种新的治疗方法，包括T细胞疫苗接种和骨髓移植。本文讨论了对风湿性疾病发病机制的当前认识，重点是类风湿关节炎。文中讨论了一些针对类风湿关节炎的新治疗方法，特别是那些作用于免疫系统的方法。由于篇幅有限，无法全面概述该领域的所有进展，因此重点介绍了一些具有代表性的策略和方法，这些策略和方法代表了目前广泛使用的各种免疫治疗方法。
